Poliovac Indications/Uses

Inactivated Poliomyelitis Vaccine (Types 1, 2 and 3) is indicated for active immunization of infants (as young as 6 weeks of age), children and adults for the prevention of poliomyelitis caused by poliovirus Types 1, 2 and 3.
INFANTS, CHILDREN AND ADOLESCENTS: General Recommendations: It is recommended that all infants (as young as 6 weeks of age), unimmunized children and adolescents not previously immunized be vaccinated routinely against paralytic poliomyelitis.
All children should receive IPV at 6-10-14 weeks of age and a booster dose at 15-18 months of age. Administration of oral polio vaccine (OPV) along with IPV should be decided as per the local vaccination guidelines. Previous clinical poliomyelitis (usually due to only a single poliovirus type) or incomplete immunization with OPV are not contraindications to completing the primary series of immunization with Inactivated Poliomyelitis Vaccine (Types 1, 2 and 3).
Children Incompletely Immunized: Children of all ages should have their immunization status reviewed and be considered for supplemental immunization as follows for adults. Time intervals between doses longer than those recommended for routine primary immunization do not necessitate additional doses as long as a final total of four doses is reached (see DOSAGE & ADMINISTRATION).
ADULTS: General Recommendations: Unimmunized adults who are potentially exposed to wild poliovirus and have not been adequately immunized should receive polio vaccination in accordance with the schedule given in DOSAGE & ADMINISTRATION.
Persons with previous poliovirus disease who are incompletely immunized or unimmunized should be given additional doses of Routine primary poliovirus vaccination of adults (generally those 18 years of age or older).
Persons with previous poliovirus disease who are incompletely immunized or unimmunized should be given additional doses of Inactivated Poliomyelitis Vaccine (Types 1, 2 and 3) if they fall into one or more categories listed previously.
The following categories of adults are at an increased risk of exposure to wild polioviruses: Travelers to regions or countries where poliomyelitis is endemic or epidemic.
Health-care workers in close contact with patients who may be excreting polioviruses.
Laboratory workers handling specimens that may contain polioviruses.
Members of communities or specific population groups with disease caused by wild polioviruses.
IMMUNODEFICIENCY AND ALTERED IMMUNE STATUS: Inactivated Poliomyelitis Vaccine (Types 1, 2 and 3) should be used in all patients with immunodeficiency diseases and members of such patients' households when vaccination of such persons is indicated. This includes patients with asymptomatic and symptomatic HIV infection, AIDS or AIDS-Related Complex, severe combined immunodeficiency, hypogammaglobulinemia, or agammaglobulinemia; altered immune states due to diseases such as leukemia, lymphoma, or generalized malignancy; or an immune system compromised by treatment with corticosteroids, alkylating drugs, antimetabolites or radiation. Immunogenicity of Inactivated Poliomyelitis Vaccine (Types 1, 2 and 3) in individuals receiving immunoglobulin could be impaired and patients with an altered immune state may or may not develop a protective response against paralytic poliomyelitis after administration of IPV.
As with any vaccine, vaccination with Inactivated Poliomyelitis Vaccine (Types 1, 2 and 3) may not protect 100% of individuals.